SanBio (OTCMKTS:SNBIF) Shares Down 74.6% – Time to Sell?
by Teresa Graham · The Cerbat GemSanBio Company Limited (OTCMKTS:SNBIF – Get Free Report)’s stock price traded down 74.6% on Wednesday. The company traded as low as C$5.51 and last traded at C$5.85. 18,762 shares traded hands during mid-day trading, an increase of 2,756% from the average daily volume of 657 shares. The stock had previously closed at C$23.00.
SanBio Stock Performance
The company has a 50 day moving average of C$10.02 and a two-hundred day moving average of C$10.08.
About SanBio
SanBio Co, Ltd. is a Japan-based biotechnology company focused on developing regenerative cell therapies for disorders of the central nervous system. The company’s research is aimed at repairing or restoring neurological function in patients with conditions that have limited treatment options, including chronic traumatic brain injury and stroke.
SanBio’s lead investigational product, SB623, is a cell-based therapy derived from allogeneic bone marrow mesenchymal stem cells. In Japan, the product received conditional and time-limited approval under the name AKUUGO Injection for the treatment of chronic motor dysfunction caused by traumatic brain injury.
Featured Stories
- Five stocks we like better than SanBio
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors